Business Wire

ADVA

12.9.2019 09:02:08 CEST | Business Wire | Press release

Share
Sify selects ADVA as technology partner to deliver managed Ethernet services

ADVA (FSE: ADV) today announced that it has been selected as the strategic technology partner of Sify Technologies Limited. Sify, the largest ICT service provider in India, is deploying the ADVA FSP 150 as the foundation of its new managed Ethernet service offering. The intelligent, multi-layer demarcation and aggregation technology will enable Sify to deliver secure, highly reliable end-to-end Ethernet services, leveraging its nationwide MPLS core network. The offering completes Sify’s ICT solution suite and empowers its end users to streamline operations, cut costs and rapidly seize new business opportunities. In addition to providing intelligent managed enterprise services, Sify will use the ADVA technology to extend its wholesale service footprint, giving more international carriers access to the Indian subcontinent.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005040/en/

“Our new managed Ethernet offering fills the final gap in our portfolio. With ADVA as our technology partner, we can roll out high-capacity Layer 2 services with total flexibility and bring intelligence and automation to the edge of our enterprise network,” said Harsha Ram, VP, telecom services, Sify. ”The ADVA FSP 150 delivers new levels of agility for service innovation. It empowers us to provide the ideal solution for the budget, strategy and technical needs of each and every customer. What’s more, with ADVA’s technology, we can put IP traffic control at the end user’s fingertips. With incredible speed and efficiency, customers can take charge of their services, managing IP addresses and altering IP routing without restriction.”

With more than 10,000 enterprise customers across the Indian subcontinent, Sify has seen an enormous increase in data demand. The ADVA FSP 150 is the ultimate response. Deployed at the customer premises, the ADVA FSP 150 demarcation solution delivers MEF-certified CE 2.0 services and provides several key advantages. It’s highly interoperable, enabling seamless integration with Sify’s existing network management system. With its comprehensive set of service assurance functions, the solution offers full visibility of service quality – an essential tool for effective SLA management. The device also provides the flexibility to quickly transition from 1Gbit/s to 10Gbit/s Ethernet services without requiring extra space and power consumption.

“Our FSP 150 technology has always been at the forefront of Ethernet access innovation. Now we’re using all of our experience as a global leader with an enormous installed base to bring scalable, SLA-assured business and cloud access to Sify’s customers. With our multi-technology platform, Sify will be able to reduce costs and significantly simplify operations,” commented Sivakumar Krishna Iyer, director, global business development, ADVA. “Our FSP 150 provides comprehensive assurance, delivering unparalleled support for SLA management. It also effortlessly expands from 1GbE to 10GbE. What’s more, our solution offers zero-touch provisioning as standard so it can easily be installed and connected by customers with no risk of error. This makes it the ideal technology to enable major operators like Sify to rollout tomorrow’s business connectivity on an enormous scale.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com .

About Sify Techologies
Sify is the largest ICT service provider, system integrator and all-in-one network solutions company on the Indian subcontinent. We’ve also expanded to the United States, with headquarters in the heart of California’s Silicon Valley. Over 10,000 businesses have become Sify customers. We also partner with other major network operators to deliver global network solutions. Our customers can access Sify services via India’s largest MPLS network. Among the very few enterprise class players in India, Sify, today has presence in more than 1,600 cities in India and in North America, the United Kingdom and Singapore. www.sifytechnologies.com

Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com

Link:

ClickThru

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye